Skip to content Skip to footer
Subscribe Now
VIEWPOINTS_Jason-Winnike_2023
VIEWPOINTS

Jason Winnike, Study Director at Metabolon Shares Insights from the Launch of its Oxysterol Targeted Panel

Shots:Jason shared his views on the launch of Metabolon, Inc.’s new Oxysterols Targeted Panel, highlighting its key features He told how the panel measures 12 oxysterols and related sterols of biological significance to identify biomarkers for the prediction and early detection of cardiovascular diseases, neurodegenerative diseases, and cancer The interview gives a profound understanding…
March 6, 2023

Read more

Thoughtspot_Saurabh_Chaubey
THOUGHTSPOT

Molecular Farming: Paving a Modern Track for Pharmaceutical Sectors (Molecular Pharming)

Technologies and innovations have transformed the world globally. Traveling to different places, interacting with new people, working remotely from home, and much more comes with evolving technologies. With all these bright perspectives, it’s also an indisputable fact that we are now more susceptible to diseases than we were a few decades ago. After the outbreak…
February 20, 2023

Read more

VIEWPOINTS_John Gabrielson_2023
VIEWPOINTS

John Gabrielson SVP, Biosimilars & Head of Business of Similis Bio (JSR Life Sciences) Shares Insights on the Partnership with Blau Farmaceutica to Co-Develop Four Biosimilar Programs

Shots: John spoke about the agreement between Similis Bio (a biosimilar partner and affiliate company of JSR) and Blau Farmaceutica to develop products and license IP for four biosimilar assets targeting indications in oncology, inflammation, and blood disordersUnder the collaboration, Similis Bio will provide full processes and associated IP for tech transfer to Blau…
February 2, 2023

Read more

Spotlight Interview_Bruce Bauer & Kendall Morrison
SPOTLIGHT

Spotlight Interview with Bruce Bauer (CEO) & Kendall Morrison (CSO) at TAE Life Sciences

PharmaShots conducted its fourth “Spotlight- Company of the Month with TAE Life Sciences”. In conversation with Bruce Bauer (CEO) & Kendall Morrison (CSO) at TAE Life Sciences, they both shared insights on TAE Life Sciences' vision, upcoming plans, technologies used, and developing products. Bruce and Kendall spoke about TAE’s novel treatment options which could potentially…
December 5, 2022

Read more

PharmaShots Interview Laurent Levy, CEO of Nanobiotix Shares Insights and Clinical Updates on its Nanoparticle Therapy
VIEWPOINTS

PharmaShots Interview: Laurent Levy, CEO of Nanobiotix Shares Insights and Clinical Updates on its Nanoparticle Therapy

Shots: Laurent spoke about the study design of its nanoparticle therapy to enhance the cancer-killing effect of radiation, which was presented at ASCO 2022Laurent also highlighted how this nanoparticle therapy can be a potential radio enhancer in various tumor types and across lines of therapyThe interview summarizes Nanobiotix’s vision to advance nanoparticles across…
August 10, 2022

Read more

PharmaShots Interview Purnanand Sarma, CEO of Immunome, Shares Insights on R&D Update IL-38 Targeting Antibody Treatment for Cancer
VIEWPOINTS

PharmaShots Interview: Purnanand Sarma, CEO of Immunome, Shares Insights on R&D Update IL-38 Targeting Antibody Treatment for Cancer

Shots: Purnanand spoke about the preclinical results of lead candidate in oncology and how its identifies IL-38 as a target to treat cancerPurnanand also talked about Immunome’s collaboration with Fox Chase Cancer Center for the further development of its prime productThe interview gives a understanding of Immunome’s goal of developing therapeutics to treat…
August 2, 2022

Read more

Exclusive_Barbara Klencke_2022
EXCLUSIVE

Barbara Klencke, CMO at Sierra Oncology (now GSK) Shares Insights on the Significant benefits obtained from the Pivotal Myelofibrosis Study

Shots:Barbara gave a comprehensive view of the P-III (MOMENTUM) clinical study results which evaluates its lead candidate in myelofibrosisSierra is now acquired by GSK (completed on 1st July 2022) resulting in GSK commercializing this prime product once approvedThe interview outlines Sierra’s (now GSK) vision to develop transformative therapies for rare cancersSmriti: Thank…
July 18, 2022

Read more

PharmaShots Interview In Conversation with Caris Life Sciences’, CBO, Brian Lamon, Where he Shares Insights on Opening of New Liquid Biopsy Laboratory Facility
VIEWPOINTS

PharmaShots Interview: In Conversation with Caris Life Sciences’, CBO, Brian Lamon, Where he Shares Insights on Opening of New Liquid Biopsy Laboratory Facility

Shots:Brian spoke about opening of its new liquid biopsy lab in Phoenix, AZ and an investment of $45M for the development of its facilitiesBrian also talked about the establishment of lab will enhance company’s molecular profiling capabilities and launch of a blood-based diagnostic assayThe interview gives a view of how Caris Life…
July 4, 2022

Read more

PharmaShots Interview In Conversation with IO Biotech’s CEO, Mai-Britt Zocca, Where she Shares Insights on the New Data from Metastatic Melanoma Trial Presented at AACR 2022
VIEWPOINTS

PharmaShots Interview: In Conversation with IO Biotech’s CEO, Mai-Britt Zocca, Where she Shares Insights on the New Data from Metastatic Melanoma Trial Presented at AACR 2022

ShotsMai-Britt talked about the P-I/II clinical trial data and study design of its lead candidate in metastatic melanoma in an e-poster presentation at AACR 2022She also spoke about IO Biotech’s unique platform with tumor defense mechanisms to kill cancer cellsThe interview gives a profound understanding of how IO Biotech is advancing to…
June 28, 2022

Read more

PharmaShots Interview In Conversation with Leonard A. Farber and James Welsh, Where they Share Insights on How Nanoparticle can Trigger an Immune Priming Effect
VIEWPOINTS

PharmaShots Interview: In Conversation with Leonard A. Farber and James Welsh, Where they Share Insights on How Nanoparticle can Trigger an Immune Priming Effect

Shots:Leonard spoke about the newly developed radiotherapy-activated nanoparticle and other cancer therapies developing in Nanobiotix’s pipelineJames shared his views on the data presented at the 2022 Annual Meeting of the American Association of Cancer ResearchThe interview provides a core understanding of Nanobiotix’s outlook to expand the utility of nanoparticles in cancer treatment…
June 15, 2022

Read more

Load more

Sign Up to Our Newsletter

Be the first to know the latest updates

[mc4wp_form id="13387" element_id="style-1"]